Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis

Leukemia Research

Volumn 29, Issue 10, 2005, Pages 1227-1232

  Agis, Hermine ^a   Sotlar, Karl ^b   Valent, Peter ^a   Horny, Hans Peter ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

BCR ABL; c kit Mutation; CML; Mastocytosis

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; STEM CELL FACTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; CASE REPORT; CELL AGGREGATION; CELL SHAPE; CHROMOSOME; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; LEUKEMIA REMISSION; MAST CELL; MICRODISSECTION; MOLECULAR CLONING; MOLECULAR WEIGHT; MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC MASTOCYTOSIS; TUMOR CELL;

EID: 23844477174     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.04.004     Document Type: Note

References (40)

1. K. Lennert, and M.R. Parwaresch Mast cells and mast cell neoplasia: a review Histopathology 3 1979 349 365
2. D.D. Metcalfe Classification and diagnosis of mastocytosis: current status J Invest Dermatol 96 1991 2S 4S
3. K.F. Austen Systemic mastocytosis N Engl J Med 326 1992 639 640
4. P. Valent Biology, classification and treatment of human mastocytosis Wien Klin Wschr 108 1996 385 397
5. P. Valent, H.-P. Horny, L. Escribano, J.B. Longley, C.Y. Li, and L.B. Schwartz Diagnostic criteria and classification of mastocytosis: a consensus proposal Leuk Res 25 2001 603 625
6. P. Valent, H.-P. Horny, C.Y. Li, J.B. Longley, D.D. Metcalfe, and R.M. Parwaresch World health organization (WHO) classification of tumours pathology and genetics E.S. Jaffe N.L. Harris H. Stein JW. Vardiman Tumours of haematopoietic and lymphoid tissues vol. 1 2001 291 302
7. P. Valent, C. Akin, W.R. Sperr, H.-P. Horny, and D.D. Metcalfe Mast cell proliferative disorders: current view on variants recognized by the World Health Organization Hematol Oncol Clin North Am 17 2003 1227 1241
8. H.-P. Horny, C. Sillaber, D. Menke, E. Kaiserling, M. Wehrmann, and B. Stehberger Diagnostic utility of staining for tryptase in patients with mastocytosis Am J Surg Pathol 22 1998 1132 1140
9. H.-P. Horny, and P. Valent Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings Leuk Res 25 2001 543 551
10. H.P. Horny, and P. Valent Histopathological and immunohistochemical aspects of mastocytosis Int Arch Allergy Immunol 127 2002 115 117
11. W.D. Travis, C.Y. Li, L.T. Yam, E.J. Bergstralh, and R.G. Swee Significance of systemic mast cell disease with associated hematologic disorders Cancer 62 1988 965 972
12. H.-P. Horny, M. Ruck, M. Wehrmann, and E. Kaiserling Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders Br J Haematol 76 1990 186 193
13. J.B. Lawrence, B.S. Friedman, W.D. Travis, V.M. Chinchilli, D.D. Metcalfe, and H.R. Gralnick Hematologic manifestation of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis Am J Med 91 1991 612 624
14. A. Pardanani, R.P. Ketterling, S.R. Brockman, H.C. Flynn, S.F. Paternoster, and B.M. Shearer CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy Blood 102 2003 3093 3096
15. A. Tefferi, and A. Pardanani Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis Int J Hematol 79 2004 441 447
16. A. Tefferi, T.L. Lasho, S.R. Brockman, M.A. Elliott, A. Dispenzieri, and A. Pardanani FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia Haematologica 89 2004 871 873
17. K. Sotlar, L. Escribano, O. Landt, S. Mohrle, S. Herrero, and A. Torrelo One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes Am J Pathol 162 2003 737 746
18. K. Sotlar, C. Fridrich, A. Mall, R. Jaussi, B. Bultmann, and P. Valent Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia Leuk Res 26 2002 979 984
19. W.R. Sperr, J.H. Jordan, M. Fiegl, L. Escribano, C. Bellas, and S. Dirnhofer Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease Int Arch Allergy Immunol 128 2002 136 141
20. W.R. Sperr, H.-P. Horny, K. Lechner, and P. Valent Clinical and biologic diversity of leukemias occurring in patients with mastocytosis Leuk Lymphoma 37 2000 473 486
21. W.R. Sperr, H.-P. Horny, and P. Valent Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis Int Arch Allergy Immunol 127 2002 140 142
22. H.-P. Horny, K. Sotlar, W.R. Sperr, and P. Valent Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge J Clin Pathol 57 2004 604 608
23. H.W. Bernd, K. Sotlar, J. Lorenzen, R. Osieka, U. Fabry, and P. Valent Acute myeloid leukaemia with t(8;21) associated with occult mastocytosis. Report of an unusual case and review of the literature J Clin Pathol 57 2004 324 328
24. K. Sotlar, H.-P. Horny, I. Simonitsch, M. Krokowski, K.J. Aichberger, and M. Mayerhofer CD25 Indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (sm) in routinely processed bone marrow biopsy specimens Am J Surg Pathol 28 2004 1319 1325
25. L. Escribano, A. Orfao, B. Diaz-Agustin, J. Villlarrubia, C. Cervero, and A. Lopez Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implication Blood 91 1998 2731 2736
26. H. Nagata, A.S. Worobec, C.K. Oh, B.A. Chowdhury, S. Tannenbaum, and Y. Suzuki Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder Proc Natl Acad Sci USA 92 1995 10560 10564
27. B.J. Longley, L. Tyrrell, S.Z. Lu, Y.S. Ma, K. Langley, and T.G. Ding Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm Nature Genet 12 1996 312 314
28. R. Fritsche-Polanz, J.H. Jordan, A. Feix, W.R. Sperr, G. Sunder-Plassmann, and P. Valent Mutation analysis of c-kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis Br J Haematol 113 2001 357 364
29. C. Akin, A.S. Kirschenbaum, T. Semere, A.S. Worobec, L.M. Scott, and D.D. Metcalfe Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis Exp Hematol 28 2000 140 147
30. W.R. Sperr, S. Walchshofer, H.-P. Horny, M. Fodinger, I. Simonitsch, and R. Fritsche-Polanz Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val Br J Haematol 103 1998 740 749
31. L.B. Schwartz, K. Sakai, T.R. Bradford, S. Ren, B. Zweiman, and A.S. Worobec The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis J Clin Invest 96 1995 2702 2710
32. L.B. Schwartz, D.D. Metcalfe, J.S. Miller, H. Earl, and T. Sullivan Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis N Engl J Med 316 1987 1622 1626
33. W.R. Sperr, J.H. Jordan, M. Fiegl, L. Escribano, C. Bellas, and S. Dirnhofer Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease Int Arch Allergy Immunol 128 2002 136 141
34. W.R. Sperr, J.H. Jordan, M. Baghestanian, H.P. Kiener, P. Samorapoompichit, and H. Semper Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia Blood 98 2001 2200 2209
35. W.R. Sperr, B. Stehberger, F. Wimazal, M. Baghestanian, L.B. Schwartz, and M. Kundi Serum tryptase measurements in patients with myelodysplastic syndromes Leuk Lymphoma 43 2002 1097 1105
36. C. Akin, K. Brockow, C. D'Ambrosio, A. Kirshenbaum, Y. Ma, and J.B. Longley Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit Exp Hematol 31 2003 686 692
37. Y. Ma, S. Zeng, D.D. Metcalfe, C. Akin, and S. Dimitrijevic The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations Blood 99 2002 1741 1744
38. M.J. Frost, P.T. Ferrao, T.P. Hughes, and L.K. Ashman Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant Mol Cancer Ther 1 2002 1115 1124
39. P. Valent, M. Ghannadan, C. Akin, M.T. Krauth, E. Selzer, and M. Mayerhofer On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts Eur J Clin Invest 34 2004 41 52
40. A. Tefferi Treatment of systemic mast cell disease: beyond interferon Leuk Res 28 2004 223 224